Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Cullinan Therapeutics, Inc. (CGEM) had Income from Continuous Operations of $-48.50M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-48.50M |
|
-- |
|
-- |
|
$55.00M |
|
$-55.00M |
|
$6.50M |
|
$-48.50M |
|
$-48.50M |
|
$-48.50M |
|
|
Income from Continuous Operations |
$-48.50M |
$-48.50M |
|
$-48.50M |
|
$-55.00M |
|
$-54.92M |
|
58.91M |
|
58.91M |
|
$-0.74 |
|
$-0.74 |
|
| Balance Sheet Financials | |
$317.77M |
|
$0.61M |
|
$261.91M |
|
$579.68M |
|
$27.35M |
|
-- |
|
$0.49M |
|
$27.84M |
|
$551.84M |
|
$551.84M |
|
$551.84M |
|
58.70M |
|
| Cash Flow Statement Financials | |
$-43.16M |
|
$36.80M |
|
-- |
|
$83.00M |
|
$76.66M |
|
$-6.35M |
|
$9.37M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
11.62 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-43.16M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-8.79% |
|
-8.79% |
|
-8.37% |
|
-8.79% |
|
$9.40 |
|
$-0.73 |
|
$-0.73 |
|